Thank you for these observations.
Conclusion: clinical oncologists care about p-values and commas but not
On 06-Apr-16 10:39, Pascal Girard wrote:
> Dear Naoto,
> In the past, Rene Bruno got one poster accepted with discussion at
> ASCO. He is our ”champion” !
> I got one accepted on model for Exp-Tumor Size – OS at European Cancer
> Congress 2013 . But I can tell you that a medical writer rewrote it
> entirely and it took 1 month to get it reviewed and corrected by
> clinicians challenging every comma and p-value.
> To give you an idea of the respective size of the meetings: ACOP
> N=500, PAGE N>600, ECC N> 10,000, ASCO N>20,000.
> So the advice I would give, is just improve the quality and
> readability of our abstract and it will meke it. By readability, I
> mean show it to an oncologist clinician. If he does not understand,
> rewrite it with the help of a medical writer …
> /With best regards / Mit freundlichen Grüßen / Cordialement/
> 7 April
> [mailto:owner-nmusers_at_globomaxnm.com] *On Behalf Of *Naoto Hayashi
> *Sent:* 06 April 2016 09:46
> *To:* jgrevel_at_btconnect.com
> *Cc:* nmusers <nmusers_at_globomaxnm.com>
> *Subject:* Re: [NMusers] ASCO and pharmacometrics
> Dear Joachim,
> Thank you so much for your reply.
> Their abstract instruction allows very small number of characters, and
> no enough room to express what we had established in this work.
> Although we described the unique results in the table, they probably
> could not understand its meaning, or the model's outcome that I was so
> excited has no meaning to oncologist.
> It seemed so nice work for me and I hope that US pharmacometrician
> society would communicate with ASCO people for our future.
> Best regards,
> Naoto Hayashi, PhD
> 2016-04-06 15:58 GMT+09:00 Joachim Grevel <jgrevel_at_btconnect.com
> Dear Naoto,
> Your experience is also mine. For a combined TTE safety and
> efficacy analysis I earned the online publication. The organisers
> do not believe in modelling, unless it describes what is already
> visible in graphs and tables of raw data.
> This is just my personal impression. I have not been to ASCO either.
> Good luck,
> *Joachim Grevel, PhD*
> Scientific Director
> BAST Inc Limited
> Science & Enterprise Park
> Loughborough University
> Loughborough, LE11 3AQ
> United Kingdom
> Tel: +44 (0)1509 222908 <tel:%2B44%20%280%291509%20222908>
> www.bastinc.eu <http://www.bastinc.eu/>
> <mailto:owner-nmusers_at_globomaxnm.com>] *On Behalf Of *Naoto Hayashi
> *Sent:* 06 April 2016 02:38
> *To:* nmusers_at_globomaxnm.com <mailto:nmusers_at_globomaxnm.com>
> *Subject:* [NMusers] ASCO and pharmacometrics
> Dear all,
> I have a question and appreciate it if somebody can answer to me.
> We had submitted an abstract to ASCO annual meeting presentation
> 2016, and its contents included a pharmacometrics work of
> quantitative safety profile analysis of an anticancer drug. The
> behave of the safety index time courses is very unique and its
> results showed a very high usefulness of this drug. The abstract
> also included the table of population PK/PD parameters that
> expressed its nature, and it was compared with the similar older
> drug safety profile and demonstrated very high safer profile
> I have some experiences to publish some articles of population
> PK/PD work in several clinical pharmacology journals in the past,
> and I was so confident for just a poster presentation in ASCO.
> However, the judgment was “publication only”, i.e. just
> presentation in online but no poster presentation and no official
> record of publication officially.
> So, my question is whether pharmacometrics work is difficult to be
> picked up in ASCO presentation. Or, was my work evaluated to have
> no worth to be presented even in poster session because the
> pharmacometrics works presented in ASCO are having very high level?
> I have never visited ASCO before, and I just want to hear opinions
> about how much of importance is considered for pharmacometrics
> work in ASCO.
> Thanks a lot in advance for your comments/thoughts.
> Best regards,
> Naoto Hayashi
> This message and any attachment are confidential and may be privileged
> or otherwise protected from disclosure. If you are not the intended
> recipient, you must not copy this message or attachment or disclose
> the contents to any other person. If you have received this
> transmission in error, please notify the sender immediately and delete
> the message and any attachment from your system. Merck KGaA,
> Darmstadt, Germany and any of its subsidiaries do not accept liability
> for any omissions or errors in this message which may arise as a
> result of E-Mail-transmission or for damages resulting from any
> unauthorized changes of the content of this message and any attachment
> thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do
> not guarantee that this message is free of viruses and does not accept
> liability for any damages caused by any virus transmitted therewith.
> Click http://www.merckgroup.com/disclaimerto access the German,
> French, Spanish and Portuguese versions of this disclaimer.
Nick Holford, Professor Clinical Pharmacology
Dept Pharmacology & Clinical Pharmacology, Bldg 503 Room 302A
University of Auckland,85 Park Rd,Private Bag 92019,Auckland,New Zealand
office:+64(9)923-6730 mobile:NZ+64(21)46 23 53 FR+33(6)62 32 46 72
"Declarative languages are a form of dementia -- they have no memory of events"
Holford SD, Allegaert K, Anderson BJ, Kukanich B, Sousa AB, Steinman A, Pypendop, B., Mehvar, R., Giorgi, M., Holford,N.H.G. Parent-metabolite pharmacokinetic models - tests of assumptions and predictions. Journal of Pharmacology & Clinical Toxicology. 2014;2(2):1023-34.
Holford N. Clinical pharmacology = disease progression + drug action. Br J Clin Pharmacol. 2015;79(1):18-27.
Received on Wed Apr 06 2016 - 07:34:26 EDT